MedTrace Logo

KAP/WTP and HPV Prevalence Studies in a Developing World Setting (Bamako, Mali)

NCT01314404 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 460

Last updated 2011-07-18

No results posted yet for this study

Summary

The Global Alliance to Immunize Against AIDS Vaccine Foundation (GAIA Vaccine Foundation or GAIA VF) proposes to carry out a Knowledge, Attitudes, and Practices (KAP) study in conjunction with a Willingness To Participate (WTP) evaluation to establish the prevalence of cervical dysplasia, to and perform Human Papillomavirus (HPV) subtyping studies in Bamako and in Sikoro-Mekin, a village within the perimeter of Bamako, the capital of Mali, West Africa. Working with experienced collaborators, we propose to carry out an HPV prevalence study (among women diagnosed with cervical cancer at Hôpital Touré), coupled with a study of Knowledge, Attitudes and Practices (KAP) and Willingness To Participate (WTP) in an HPV vaccine study among individuals living in Sikoro-Mekin. These studies will lay the groundwork for a phase IV study of Gardasil® at the same site, which would be an important step forward for West Africa.

Conditions

  • Human Papillomavirus

Sponsors & Collaborators

  • Merck Sharp & Dohme LLC

    collaborator INDUSTRY

  • Global Alliance to Immunize Against AIDS Vaccine Foundation

    lead OTHER

Principal Investigators

  • Anne De Groot, M.D. · Global Alliance to Immunize Against AIDS (GAIA) Vaccine Foundation

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-03-31
Primary Completion
2012-03-31
Completion
2012-09-30

Countries

  • Mali

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01314404 on ClinicalTrials.gov